Cloud-clone
SKU(재고 관리 코드):LMC006Hu
Magnetic Luminex Assay Kit for Interleukin 8 Receptor Beta (IL8Rb) ,etc.
Magnetic Luminex Assay Kit for Interleukin 8 Receptor Beta (IL8Rb) ,etc.
Product No.
LMC006Hu
Organism Species
Homo sapiens (Human).
Sample Type
tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.05-50ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.017 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Interleukin 8 Receptor Beta (IL8Rb) ,etc..
No significant cross-reactivity or interference between Interleukin 8 Receptor Beta (IL8Rb) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Interleukin 8 Receptor Beta (IL8Rb) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Interleukin 8 Receptor Beta (IL8Rb) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 86-103 | 91 |
| EDTA plasma(n=5) | 93-101 | 97 |
| heparin plasma(n=5) | 97-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Interleukin 8 Receptor Beta (IL8Rb) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Interleukin 8 Receptor Beta (IL8Rb) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Interleukin 8 Receptor Beta (IL8Rb) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-104% | 89-102% | 91-99% | 89-98% |
| EDTA plasma(n=5) | 80-91% | 81-88% | 87-102% | 92-101% |
| heparin plasma(n=5) | 88-97% | 79-94% | 81-94% | 81-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:IL8Rb) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Theranostics | Direct Macromolecular Drug Delivery to Cerebral Ischemia Area using Neutrophil-Mediated Nanoparticles. pubmed:28900508 |
| Scientific Reports | Role of ceramide synthase 2 in G-CSF signaling and G-CSF-R translocation into detergent-resistant membranes Pubmed: 30679689 |
| Pathogenic Functions of Tumor Necrosis Factor Receptor-associated Factor 6 Signaling following Traumatic Brain Injury | |
| The neuroprotection of hyperbaric oxygen therapy against traumatic brain injury via NF-¦ÊB/MAPKs-CXCL1 signaling pathway |
Share
